Overall, our findings show that treatment with HK2 inhibitor or depletion of pericyte-HK2 by shRNA can enhance blood flow and perfusion leading to increased intratumoral drug delivery and efficacy against tumor growth, whilst decreasing tumor hypoxia without affecting blood vessel density and pericyte coverage (Fig. 7). The gene discussed is HK2; the disease is neoplasm.